Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0002100121-26-000087
Filing Date
2026-04-28
Accepted
2026-04-28 16:05:30
Documents
1
X0202

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 5653
  Complete submission text file 0002100121-26-000087.txt   7667
Mailing Address 177 E COLORADO BLVD SUITE 700 PASADENA CA 91105
Business Address 177 E COLORADO BLVD SUITE 700 PASADENA CA 91105 626-696-4702
ARROWHEAD PHARMACEUTICALS, INC. (Subject) CIK: 0000879407 (see all company filings)

EIN.: 460408024 | State of Incorp.: DE | Fiscal Year End: 0930
Type: SCHEDULE 13G | Act: 34 | File No.: 005-48710 | Film No.: 26907587
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 100 VANGUARD BLVD MALVERN PA 19355
Business Address 100 VANGUARD BLVD MALVERN PA 19355 610-669-6148
VANGUARD PORTFOLIO MANAGEMENT LLC (Filed by) CIK: 0002100121 (see all company filings)

EIN.: 392888838 | State of Incorp.: PA | Fiscal Year End: 1231
LEI: 529900YN99W7NU4H6B84
Type: SCHEDULE 13G